Otonomy, Inc.

125 articles with Otonomy, Inc.

• Otonomy to Participate in Four Upcoming Investor Conferences

  9/2/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in four upcoming virtual investor conferences. Citi’s 15 th Annual BioPharma Virtual Conference on September 9-10, 2020: 1 on 1 investor meetings.   H.C. Wainwright 22nd Annual Global Investment Conference: presentation on September 14, 2020 at 12 p.m. ET (

• Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  8/4/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended June 30, 2020 and provided an update on its product pipeline and corporate activities

• Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss ProgramCompound has potential to benefit patients with severe hearing loss

  8/3/2020

  Otonomy, Inc. announced an exclusive license agreement with KYORIN Pharmaceutical Co., Ltd. that provides Otonomy with exclusive worldwide rights to develop, manufacture and commercialize a novel compound for the treatment of sensorineural hearing loss.

• Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate UpdateWebcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020

  7/28/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter of 2020 and provide a corporate update at 5 p.m. EDT on August 4, 2020.

• Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  7/13/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closing of its previously announced underwritten public offering of 17,275,000 shares of its common stock, which includes the underwriters' full exercise of their option to purchase additional shares and pre-funded

• 

  Clinical Catch-Up: July 6-10

  7/13/2020

  Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.

• Otonomy Announces Pricing of $60.1 Million Public Offering - July 09, 2020

  7/9/2020

  Otonomy, Inc. announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price to the public of $3.25 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 4,000,000 shares of its common stock at a purchase price of $3.249 per each pre-funded warrant...

• Otonomy Announces Proposed Public Offering - July 08, 2020

  7/8/2020

  Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced that it has commenced an underwritten public offering of its common stock.

• Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus

  7/6/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive top-line results from the Phase 1/2 clinical trial of OTO-313 in patients with persistent tinnitus of at least moderate severity.

• Otonomy Provides Update on OTIVIDEX® ProgramManagement will review the OTIVIDEX statistical analysis plan update together with the positive top-line OTO-313 Phase 1/2 trial results during a conference call today at 4:30 p.m. ET

  7/6/2020

  Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, provided an update on the statistical analysis plan related to the ongoing Phase 3 clinical trial of OTIVIDEX in Ménière’s disease.

• ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO® (ciprofloxacin otic suspension), the First and Only Single-Dose Treatment for Acute Otitis Externa (Swimmer's Ear)

  6/17/2020

  ALK gains exclusive rights to market OTIPRIO in U.S. for acute otitis externa including to ear, nose and throat (ENT) physicians, pediatricians and select primary care physicians

• Otonomy Provides Update on Clinical Trials and Development Programs

  6/15/2020

  Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, provided an update on its product pipeline and the timeline to results for the company’s three ongoing clinical trials, including the Phase 3 trial of OTIVIDEX in Ménière’s disease.

• Otonomy to Present at Raymond James 2020 Human Health Innovation Conference

  6/11/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to present a company overview at the Raymond James 2020 Human Health Innovation Conference

• Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020

  6/10/2020

  Otonomy, Inc. announced that due to the health, safety and travel concerns of stockholders and federal, state and local government recommendations and restrictions imposed in response to the novel coronavirus pandemic, the location of its 2020 Annual Meeting of Stockholders has changed.

• Otonomy to Host Pipeline Program Update Conference Call and Webcast

  6/8/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will host a conference call and webcast to review the status and timeline to results for the company’s three ongoing clinical trials including the Phase 3 trial of OTIVIDEX® in Ménière’s disease at 4:30 p.m.

• Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program

  5/12/2020

  Otonomy, Inc. announced preclinical results from the company’s gene therapy collaboration with Applied Genetic Technologies Corporation that support the selection of a product candidate for development as a treatment for gap junction beta-2 deficiency, the most common cause of congenital hearing loss.

• Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate UpdateConference call to review status of clinical trials and timing to results to be held in June

  5/7/2020

  Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, reported financial results for the quarter ended March 31, 2020 and provided an update on its product pipeline and corporate activities.

• 

  Clinical Catch-Up: April 6-10

  4/13/2020

  It was a very busy week for clinical trial news. Here’s a look.

• Otonomy Provides Business Update Related to COVID-19 Pandemic

  4/9/2020

  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a business update related to the COVID-19 pandemic.

• Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

  2/27/2020

  Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, reported financial results for the fourth quarter and year ended December 31, 2019 and provided an update on its product pipeline and corporate activities.